Skip to main content
Log in

The Role of Ezetimibe in the Treatment of Cardiovascular Disease

  • Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript


Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Despite the success of treatment of CVD with statin therapy, a number of patients remain at high risk for CVD. Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C). A number of clinical studies evaluating the use of ezetimibe therapy have resulted in discordant data regarding its safety and efficacy. In this review, we discuss the findings from these studies as well as potential indications for the use of ezetimibe for LDL-C lowering and cardiovascular event reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–e322.

    Article  PubMed  Google Scholar 

  2. Smith MEB, Lee NJ, Haney E, Carson S. In: Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5. Portland (OR); 2009.

  3. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.

    Article  PubMed  Google Scholar 

  5. Altmann SW, Davis Jr HR, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201–4.

    Article  CAS  PubMed  Google Scholar 

  6. van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 2000;129(8):1748–54.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015;65(15):1552–61.

    Article  CAS  PubMed  Google Scholar 

  8. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004;93(12):1487–94.

    Article  CAS  PubMed  Google Scholar 

  9. Capps N. Total and low-density lipoprotein cholesterol responses to ezetimibe in clinical practice. Int J Clin Pract. 2006;60(7):867–9.

    Article  CAS  PubMed  Google Scholar 

  10. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415–27.

    PubMed Central  CAS  PubMed  Google Scholar 

  11. Expert Panel on Detection E. Treatment of high blood cholesterol in a: executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97.

    Article  Google Scholar 

  12. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin versus atorvastatin (VYVA) study. Am Heart J. 2005;149(3):464–73.

    Article  CAS  PubMed  Google Scholar 

  13. Zetia [package insert]. Whitehouse Station, NJ: Merck & CO., Inc. [].

  14. Escola-Gil JC, Quesada H, Julve J, Martin-Campos JM, Cedo L, Blanco-Vaca F. Sitosterolemia: diagnosis, investigation, and management. Curr Atheroscler Rep. 2014;16(7):424.

    Article  PubMed  Google Scholar 

  15. Tsubakio-Yamamoto K, Nishida M, Nakagawa-Toyama Y, Masuda D, Ohama T, Yamashita S. Current therapy for patients with sitosterolemia—effect of ezetimibe on plant sterol metabolism. J Atheroscler Thromb. 2010;17(9):891–900.

    Article  CAS  PubMed  Google Scholar 

  16. Kastelein JJ, Sager PT, de Groot E, Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J. 2005;149(2):234–9.

    Article  CAS  PubMed  Google Scholar 

  17. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–43. Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) was one of the first major trials to study the effect of ezetimibe superimposed on statin therapy in terms of its effect on cIMT (a marker of subclinical atherosclerosis).

    Article  CAS  PubMed  Google Scholar 

  18. Toth PP, Ballantyne CM, Davidson MH, et al. Changes in prescription patterns before and after reporting of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012;6(2):180–91.

    Article  PubMed  Google Scholar 

  19. Ross JS, Frazee SG, Garavaglia SB, et al. Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010. JAMA internal medicine. 2014;174(9):1486–93.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Bots ML, Baldassarre D, Simon A, et al. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J. 2007;28(4):398–406.

    Article  PubMed  Google Scholar 

  21. Landray M, Baigent C, Leaper C, et al. The second United Kingdom heart and renal protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis. 2006;47(3):385–95.

    Article  CAS  PubMed  Google Scholar 

  22. Baigent C, Landry M. Study of heart and renal protection (SHARP). Kidney Int Suppl. 2003;84:S207–10.

    Article  PubMed  Google Scholar 

  23. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–56.

    Article  PubMed  Google Scholar 

  25. Holme I, Boman K, Brudi P, et al. Observed and predicted reduction of ischemic cardiovascular events in the simvastatin and ezetimibe in aortic stenosis trial. Am J Cardiol. 2010;105(12):1802–8.

    Article  CAS  PubMed  Google Scholar 

  26. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352(23):2389–97.

    Article  CAS  PubMed  Google Scholar 

  27. Otto CM. Calcific aortic stenosis—time to look more closely at the valve. N Engl J Med. 2008;359(13):1395–8.

    Article  CAS  PubMed  Google Scholar 

  28. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97. IMPROVE-IT was the first and largest randomized control trial to demonstrate an incremental benefit from addition of ezetimibe therapy on top of statin therapy in long-term cardiovascular outcomes in patients presenting with ACS.

    Article  CAS  PubMed  Google Scholar 

  29. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

    Article  Google Scholar 

  30. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–504.

    Article  CAS  PubMed  Google Scholar 

  31. Virani SS, Akeroyd JM, Nambi V, et al. Implications for ezetimibe therapy use based on IMPROVE-IT criteria. Am J Med. 2015. This study from the Veterans Affairs health care system evaluates the impact of IMPROVE-IT trial in terms of what percent of ACS population might be eligible for ezetimibe therapy based on IMPROVE-IT criteria.

  32. Ezetimibe reduces cardiovascular events in diabetics with recent acute coronary syndrome [].

  33. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008;359(13):1357–66.

    Article  CAS  PubMed  Google Scholar 

  34. Alsheikh-Ali AA, Karas RH. Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post-marketing analysis. J Clin Lipidol. 2009;3(2):138–42.

    Article  PubMed  Google Scholar 

  35. No Diabetes Increase With Ezetimibe in IMPROVE-IT [].

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Salim S. Virani.

Ethics declarations

Conflict of Interest

Anandita Agarwala, Zaid Kajani, Michael D. Miedema, and Salim S. Virani declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Coronary Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Agarwala, A., Kajani, Z., Miedema, M.D. et al. The Role of Ezetimibe in the Treatment of Cardiovascular Disease. Curr Atheroscler Rep 18, 8 (2016).

Download citation

  • Published:

  • DOI: